|Line 33:||Line 33:|
<!-- [http://www.synthesis.cc http://www.synthesis.cc/assets_c/2010/05/carlson_longest_sDNA_2010-thumb-500x457.png]
Revision as of 22:33, 22 January 2013
A large number of parts have been made by the synthetic biology community. Many can be found as part of the Registry of Standard Biological Parts. These modular genetic components are designed to be easy to acquire and assemble to facilitate the building of more complex biological devices. To learn more about the Registry and the biological parts known as BioBricks™, see the entry for the iGEM Registry.
The Registry of Standard Biological Parts is an attempt to create an annotated and characterized repository of biological parts. It is motivated in part because synthetic biologists rely on the ability to make testable biological units. This means that the ability to gather, manipulate, or even create genetic material is vital for "doing" synthetic biology. This page details how to create DNA from small (<60 nts) oligonucleotides to larger genes (~400 nts) to genome sized (~500 ,000 nts) biological units.
Gene synthesis, or artificial gene synthesis, refers to the process of creating a nucleic acid template for a gene in vitro, without the requirement of a preexisting DNA template. Soon after the elucidation of the genetic code and the description of the central dogma of molecular biology, there arose a need to synthesize genes de novo in order to study their biological function both in the test tube and in model organisms. Chemical synthesis of DNA has grown from an expensive and time-consuming process into a viable commercial industry capable of high-throughput manufacture of almost any scale of custom DNA molecules in almost any context. This allows species-specific gene optimization, creation of genes from rare or dangerous sources, and combinatorial assembly of any DNA sequence that can be chemically synthesized, even including non-traditional bases. The most advanced applications of gene synthesis have been applied to the recent creation of completely synthetic minimal genomes in prokaryotes.
Despite nearly four decades of progress in gene synthesis technologies, most DNA sequences used in modern molecular biology are assembled in part or in whole from naturally occurring templates. However this limits the scope and applications to previously existing genes and the results of large-scale genomic surveys of novel genes from nature. Modern gene synthesis relies heavily on advancements in chemical DNA oligonucleotide synthesis, with the primary challenges being scale, cost, fidelity and the eventual assembly of complete gene products.
A directory of commercial gene synthesis providers can be found at Genespace. The company biomatik is not included on this list.
History of Gene Synthesis
Gene synthesis predates the invention of restriction enzymes and molecular cloning techniques by several years. The first gene to be completely synthesized in vitro was a 77-nt alanine transfer RNA by the laboratory of Har Gobind Khorana in 1972 . This was the result of nearly five years of work and resulted in a DNA template without promoter or transcriptional control sequences. The first peptide- and protein-producing synthetic genes were created in 1977 and 1979, respectively [2, 3]. Steady advancement has led to recent synthesis of complete gene clusters tens of thousands of nucleotides in length, and ultimately a bacterial genome approximately 1.2 million bases in length.
Regardless of the length of the eventual product, synthetic DNA constructs are built from some combination of short DNA oligonucleotides. These oligonucleotides are later assembled into a complementary DNA duplex, amplified and inserted into their final genetic context.
Oligonucleotides are chemically synthesized from DNA phosphoramidite monomers. Briefly, activated phosphoramidite monomers are added in the 3' to 5' direction using a cyclical activation and blocking chemistry to obtain a DNA polymer linked by phosphodiester bonds.
Chemical synthesis is currently limited to oligonucleotides of about 200 nt in length.
Currently, synthetic DNA oligonucleotides less than 60 Bases can be obtained for about #0.35 USD/Base 
list of BioBrick Foundation Standards
Polymerase Chain Reaction
TOPO TA cloning (invitrogen)
SOE (splice by overlap extension) pcr
-In-Fusion (Clontech) poxvirus DNA polymerase with 3′–5′ exonuclease activity
-In-Fusion BioBrick Assembly
-cold fusion (SBI)
-SLIC sequence and ligation independent cloning T4 DNA polymerase (exonuclease)
-Gibson T5 exonuclease, Phusion polymerase, Taq ligase
-CPEC circular polymerase extension cloning
-SLiCE (Seamless Ligation Cloning Extract) in vitro homologous recombination
-Fast Seamless Cloning (Dogene)
-CloneEZ kit (Genescript)
- e coli
- s. cerevisiae
More cloning strategies found here
- Weber E, Engler C, Gruetzner R, Werner S, and Marillonnet S. . pmid:21364738.
- Hughes RA, Miklos AE, and Ellington AD. . pmid:21601682.
Gene Synthesis Review
- Werner S, Engler C, Weber E, Gruetzner R, and Marillonnet S. . pmid:22126803.
- Sarrion-Perdigones A, Falconi EE, Zandalinas SI, Juárez P, Fernández-del-Carmen A, Granell A, and Orzaez D. . pmid:21750718.
- Engler C, Kandzia R, and Marillonnet S. . pmid:18985154.
- Quan J and Tian J. . pmid:19649325.
- Gibson DG, Benders GA, Andrews-Pfannkoch C, Denisova EA, Baden-Tillson H, Zaveri J, Stockwell TB, Brownley A, Thomas DW, Algire MA, Merryman C, Young L, Noskov VN, Glass JI, Venter JC, Hutchison CA 3rd, and Smith HO. . pmid:18218864.
- Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, and Smith HO. . pmid:19363495.
T5 exonuclease recombination
- Li MZ and Elledge SJ. . pmid:17293868.
- Li MZ and Elledge SJ. . pmid:22328425.
- Sleight SC, Bartley BA, Lieviant JA, and Sauro HM. . pmid:20385581.
- Zhu B, Cai G, Hall EO, and Freeman GJ. . pmid:17907578.
- Benoit RM, Wilhelm RN, Scherer-Becker D, and Ostermeier C. . pmid:16289702.
- Geu-Flores F, Nour-Eldin HH, Nielsen MT, and Halkier BA. . pmid:17389646.
- Gibson DG. . pmid:19745056.
- Horton RM, Cai ZL, Ho SN, and Pease LR. . pmid:2357375.
- Czar MJ, Anderson JC, Bader JS, and Peccoud J. . pmid:19111926.
- Stemmer WP, Crameri A, Ha KD, Brennan TM, and Heyneker HL. . pmid:7590320.
- Aslanidis C and de Jong PJ. . pmid:2235490.
- Aslanidis C, de Jong PJ, and Schmitz G. . pmid:7580902.
- Li C and Evans RM. . pmid:9321675.
- Angrand PO, Daigle N, van der Hoeven F, Schöler HR, and Stewart AF. . pmid:10446259.
lambda Red recombinase
- Hartley JL, Temple GF, and Brasch MA. . pmid:11076863.
Gateway lambda Int
- Khalil AM, Julius JA, and Bachant J. . pmid:17702758.
Gateway lambda Cre
- Larionov V, Kouprina N, Graves J, Chen XN, Korenberg JR, and Resnick MA. . pmid:8552668.
Transformation-associated recombination (TAR) cloning
- j5 DNA Assembly Design Automation Software doi: 10.1021/sb2000116
- Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, Merryman C, Vashee S, Krishnakumar R, Assad-Garcia N, Andrews-Pfannkoch C, Denisova EA, Young L, Qi ZQ, Segall-Shapiro TH, Calvey CH, Parmar PP, Hutchison CA 3rd, Smith HO, and Venter JC. . pmid:20488990.
- Li MZ and Elledge SJ. . pmid:15731760.
MAGIC, bacterial mating approach
- Zhang Y, Werling U, and Edelmann W. . pmid:22241772.